NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026
SANTA ANA, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. OTC:NKGN (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced tha…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.